Cytek Biosciences Inc (STU:8EQ)
€ 6.1 0 (0%) Market Cap: 798.13 Mil Enterprise Value: 547.18 Mil PE Ratio: 0 PB Ratio: 2.16 GF Score: 60/100

Q4 2023 Cytek Biosciences Inc Earnings Call Transcript

Feb 28, 2024 / 10:00PM GMT
Release Date Price: €8
Operator

Good day and thank you for standing by, and welcome to the Cytek Biosciences fourth quarter and full-year 2023 earnings conference call. (Operator Instructions)

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Paul Goodson, Head of Investor Relations. Please go ahead.

Paul Goodson
Cytek Biosciences Inc - Head of Investor Relations

Thank you, operator. Earlier today, Cytek Biosciences released financial preliminary results for the quarter and year ended December 31, 2023. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an e-mail to investors at cytekbio.com. Joining me today from Cytek are Wenbin Jiang, CEO; and Patrick Jeanmonod, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during the call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot